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Abstract
Nutritional substances associated to some hormones enhance liver regeneration when injected intraperitoneally, being denomi-
nated hepatotrophic factors (HF). Here we verified if a solution of HF (glucose, vitamins, salts, amino acids, glucagon, insulin, 
and triiodothyronine) can revert liver cirrhosis and how some extracellular matrices are affected. Cirrhosis was induced for 14 
weeks in 45 female Wistar rats (200 mg) by intraperitoneal injections of thioacetamide (200 mg/kg). Twenty-five rats received 
intraperitoneal HF twice a day for 10 days (40 mL·kg-1·day-1) and 20 rats received physiological saline. Fifteen rats were used 
as control. The HF applied to cirrhotic rats significantly: a) reduced the relative mRNA expression of the genes: Col-α1 (-53%), 
TIMP-1 (-31.7%), TGF-β1 (-57.7%), and MMP-2 (-41.6%), whereas Plau mRNA remained unchanged; b) reduced GGT (-43.1%), 
ALT (-17.6%), and AST (-12.2%) serum levels; c) increased liver weight (11.3%), and reduced liver collagen (-37.1%), regen-
erative nodules size (-22.1%), and fibrous septum thickness. Progranulin protein (immunohistochemistry) and mRNA (in situ 
hybridization) were found in fibrous septa and areas of bile duct proliferation in cirrhotic livers. Concluding, HF improved the 
histology and serum biochemistry of liver cirrhosis, with an important reduction of interstitial collagen and increased extracelullar 
matrix degradation by reducing profibrotic gene expression.
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Liver transplantation is the only definitive treatment in 
some cases of human chronic cirrhosis (1). Nutritional sup-
port has been shown to be helpful in some liver diseases 
(2,3). In fact, liver proliferation can be modulated by dietary 
factors that interfere with hepatic regeneration. Studies 
dealing with nutritional modulation of hepatic regeneration 
and growth by stimulation of hepatocyte proliferation with 
hepatotrophic factors (HF) found in food have been pub-
lished (2-6). Hepatic mass and DNA increase associated 
with reduction of the fibrotic fraction in the extracellular matrix 
was observed after 10 days of intraperitoneal treatment 
with HF in normal rats. The intraperitoneal route may have 
contributed to liver mass increase and collagen reduction 
since this route is functionally very close to a portal admin-
istration. HF usually consist of vitamins, salts, amino acids, 
and hormones (triiodothyronine, insulin and glucagon) (4). 
Due to previous results obtained for normal liver, we applied 
HF treatment to cirrhotic livers to investigate if this solution 
would be effective in reducing the cirrhotic condition and to 
identify some of the mechanisms of its effect. The relative 
expression activities of matrix metalloproteinase-2 (MMP-2), 
transforming growth factor-β1 (TGF-β1), tissue inhibitor of 
metalloproteinase-1 (TIMP-1), collagen-α1, and plasmino-
gen activator urokinase (Plau) were evaluated by real-time 
PCR. Total hepatic collagen volumetric proportion and 
regenerative nodules were measured, and histopathologic 
and hepatic function analyses were performed. Additionally, 
we characterized the expression of progranulin protein and 
mRNA in cirrhotic and non-cirrhotic livers. Progranulin is 
a growth factor involved in tumorigenesis, wound repair, 
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neovascularization, inflammation, cell migration and mito-
sis (7), and cell survival (8). Progranulin expression was 
high in a mouse model of early diet-induced non-alcoholic 
steatohepatitis (9), and was recently identified in cultured 
primary and immortalized hepatic stellate cells (10), but 
it is not expressed in normal hepatocytes (11). Given the 
association of progranulin with fibrosis following injury (12), 
with early liver disease, and with hepatic stellate cells in 
culture, we postulated that it may play a role in hepatic 
fibrosis/cirrhosis in vivo. 
Material and Methods
Experimental design
Sixty female Wistar rats (185-211 g) were used in ac-
cordance with the ethical guidelines of the University of São 
Paulo. The rats were randomly divided into three groups: 
control group (15 rats not submitted to any experimental 
treatment), cirrhotic rats treated with hepatotrophic factors 
(HF group, N = 25) and cirrhotic rats treated with physi-
ological saline (PS group, N = 20). Cirrhosis was induced 
by intraperitoneal injections of 200 mg/kg 4% thioacetamide 
(TAA) in saline, three times a week for 14 weeks with a 20% 
increase by the 7th week. 
Hepatotrophic factor solution was composed of 2 solu-
tions: a) salts, hormones and vitamin solutions containing 
104 g glucose, 2 mg pyridoxine, 2 mg calcium pantothenate, 
30 mg thiamine, 4 mg riboflavin phosphate, 1.43 g potassium 
chloride, 1.50 g sodium bicarbonate, 50 mg nicotinamide, 
750 mg potassium monophosphate, 500 mg magnesium 
sulfate, 500 mg vitamin C, 62.5 IU insulin, 0.625 mg glu-
cagon, 2.5 mg folic acid, 31.25 μg vitamin B12, 3.125 mg 
zinc sulfate, and 300 mL distilled water (q.s.). b) the amino 
acid solution was composed of 180 mg L-tryptophan, 530 
mg L-valine, 1060 mg L-arginine (base), 460 mg L-histidine 
(base), 1030 mg L-alanine, 380 mg L-asparagine, 270 mg 
L-aspartic acid, 270 mg L-glutamic acid, 30 mg L-cystine, 
260 mg L-ornithine, 840 mg L-proline, 250 mg L-serine, 
160 mg L-tyrosine, 800 mg L-glycine, and 200 mL distilled 
water (q.s.). Both solutions were mixed for a total volume 
of 500 mL. Triiodothyronine was added to the HF solution 
just before the use to reach a concentration of 2.26 μg per 
200 g of live weight.
All animals were weighed weekly. Ten days after the 
end of the cirrhosis induction period, a liver biopsy from 
each rat (2 x 3 x 3 mm) was obtained from the PS and HF 
groups and the rats were then allowed to rest for 10 days 
before the beginning of HF or PS treatment. 
HF rats received an intraperitoneal injection of HF 
solution twice a day for 10 days (40 mL·kg-1·day-1) and 
PS animals were injected with physiological saline. After 
treatment, the animals of all groups were euthanized and 
liver samples were collected. Liver weight, liver volume and 
liver to carcass index were measured. Liver/carcass (LC) 
index corresponded to liver weight x 100 / carcass weight 
(body weight without viscera).
Anesthesia and biopsy surgery
Ten days after the end of the cirrhosis induction period, 
the animals from the HF and PS groups were anesthetized 
with isofluorane in 100% oxygen through a Magill circuit and 
a liver fragment was excised through an abdominal incision. 
The experimental design was in accordance with the ethical 
guidelines of the University of São Paulo.
Histopathological examination
Liver samples from biopsies and from the end of treat-
ment with HF or PS were fixed in metacarn and embedded 
in paraplast. Tissue sections (5 μm) were stained with 
hematoxylin-eosin and picrosirius (13).
Volumetric proportion of collagen in the liver
Quantitative analysis was performed using the Kontron 
Zeiss morphometry software KS 400.3 (Carl Zeiss Vision 
GmbH, Germany). Parenchymal collagen was determined 
by picrosirius staining. The picrosirius-stained area was 
measured in 15 microscope fields of the same size from 
each of 10 animals randomly selected from each group 
(PS and HF). Data are reported as percent collagen area in 
the microscopic field, which is equivalent to the volumetric 
proportion of collagen in the liver.
Determination of regenerative nodules
Quantitative analysis was performed as described 
above. The number of parenchymal regenerative nodules 
was counted in 10 rats selected at random from each ex-
perimental group (PS and HF). Counts were performed in 
picrosirius-stained liver sections with a 4X objective, for a 
total of 15 microscopic fields per rat. 
Serum analysis 
Blood samples were obtained by cardiac puncture from 
all animals just before euthanasia. Alanine aminotransferase, 
aspartate aminotransferase, and gamma-glutamyltrans-
ferase were determined with a VetTest Blood Chemistry 
Analyzer (USA).
RNA purification and real-time PCR
Total RNA was extracted from 40 mg of frozen liver 
with the Trisol reagent (Invitrogen Life Technologies, USA). 
Real-time PCR was performed using the ABI Prism® 7000 
Sequence Detection System (Applied Biosystems, USA) and 
the TaqMan Universal Master Mix (Applied Biosystems). The 
β-actin forward primer (ACCATGAAGATCAAGATCAT), the 
β-actin reverse primer (AGATTACTGCCCTGGCTCCTA), 
and the internal β-actin TaqMan probe (FAM-CCACCAAT 
CCACACAGAGTACTT) were used to detect the housekeep-
ing gene β-actin. The primers collagen-α1 (Rn00801649), 
TGF-β1 (Rn00695755m1), TIMP-1 (Rn00587558m1), MMP-
2 (Rn01538167m1), and Plau (Rn0095755m1) were from 
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Applied Biosystems. Analysis of relative gene expression 
data was performed by the 2D-DCT method (14). 
In situ hybridization for progranulin
Five-micrometer thick tissue sections fixed in metacarn 
were postfixed with 4% paraformaldehyde, treated with 0.2 
M HCl (5 min) and permeabilized with proteinase K (Roche, 
USA). After washing with 0.5 M sodium citrate solution (SSC), 
the sections were incubated for 3 h at 42°C with hybridiza-
tion buffer (5X SSC, 5X Denhardt’s solution, 50% deionized 
formamide and 250 μg/mL progranulin tRNA). Sections were 
incubated overnight with RNA probes (anti-sense BamH1 
and sense EcoR1, 1:100) in hybridization buffer containing 
tRNA as carrier after denaturation of the probe solutions. 
After hybridization, stringency washes were performed in 
SSC baths. Immunological detection was carried out with the 
Dig AP-conjugate (Roche), 1:1000 in 1 M maleic acid, 0.15 
M NaCl, pH 7.5, treated DEPC buffer solution. The reaction 
was visualized with NBT and BCIP (Roche). 
Immunohistochemistry
Progranulin. Antigen retrieval was performed by expos-
ing the sections to 10 mM sodium citrate buffer, pH 6.0, 
in a microwave oven at 900 watts for 20 min. Sections 
were kept in 5% H2O2 for 30 min, followed by 3% bovine 
serum albumin in 0.1% Tween-20-PBS solution for 3 h to 
block endogenous peroxidase and nonspecific staining, 
respectively. Rabbit anti-human progranulin antibody was 
diluted in antibody diluent (Dako, S0809, USA) and ap-
plied to the sections overnight at 4°C. This antibody has 
been previously demonstrated to cross-react specifically 
with rat progranulin (Bateman A, unpublished results) and 
other species (15). The reaction products were visualized 
with the LSAB2 System-HRP kit (Dako Cytomation, USA) 
DAB-visualization system.
Bromodeoxyuridine (BrdU). After endogenous peroxi-
dase blocking with 3% H2O2, sections were incubated with 
0.5 N HCl for 1 h at 37°C. After washing in PBS, the sections 
were incubated with primary mouse anti-BrdU antibody 
1:100 (Amersham Biosciences, USA) for 1 h at 37°C. The 
Dako EnVision kit (Dako Cytomation) visualization system 
was used to visualize the DAB reaction. Negative controls 
(sections processed without the primary or secondary 
antibody and BrdU-free tissue) were prepared for all im-
munohistochemistry methods. 
Statistical analysis
The mean data for the various groups were compared by 
ANOVA followed by the Fisher or Newman-Keuls post-test 
and pairs of means were compared by the Student t-test 
or the paired Student t-test for paired samples (biopsy-
treatment). The level of significance was set at P < 0.05 in 
all analyses and when a result is reported to be different in 
any way (higher, lower, more or less) compared with another, 
they were statistically different.
Results
Macroscopy and animal weight
Rats treated with TAA for 14 weeks developed cirrho-
sis, which was macronodular in most cases. The average 
rat weight was 200.2 ± 6.1 g. The HF and PS groups lost 
weight during TAA administration, regaining it from the 4th 
to the 7th week, when the dose of TAA was increased by 
20%. The weight then dropped again until the 9th week, 
increasing thereafter until the 14th week when the experi-
ment was terminated.
Hepatic measurements
The final body weight of the liver of rats treated with HF 
(9.9 ± 1.1 g) was 11.3 and 33.8% higher than that of rats 
from the PS (8.9 ± 1.1 g) and control (7.4 ± 0.9 g) groups, 
respectively. Likewise, the liver volume of the HF group (9.2 
± 1 cm3) was 11.3% higher than that of the PS group (8.2 ± 
1 cm3) and 34.3% higher than that of the control group (6.8 
± 0.8 cm3). In addition, the LC index was 11.8 and 47.5% 
(5.9 ± 0.6) higher in the HF group than in the PS (5.3 ± 0.6) 
and control (4.0 ± 0.6) groups, respectively. In all cases the 
values were statistically significant.
Histopathology
Rats treated with TAA (HF and PS) showed severe cir-
rhosis and loss of normal parenchymal architecture, with 
fibrous septa forming collagen bridges between hepatic 
triads delineating small and large regenerative nodules of 
hepatocytes and necrosis. Centrolobular veins were not 
observed (Figure 1a). Cytoplasmic vacuolization, mega-
locytosis, bile duct proliferation, and injury to hepatocyte 
nuclei were observed.
The HF group showed reorganization and restoration of 
the normal parenchymal architecture, with thinner fibrous 
septa. There were fewer regenerative nodules of increased 
size (Figure 1b) and centrolobular veins reappeared. Re-
duction of cytoplasmic vacuolization, megalocytosis, bile 
duct proliferation, and nuclei injury were evident, although 
the microscopic architecture was still different from control 
(Figure 1c). Bile duct proliferation was found in 62.5% of 
the liver sections from the PS group and in 38.9% of the 
sections from the HF group. This difference was statistically 
significant. 
Determination of collagen and regenerative nodules 
All comparisons after treatment were paired with the 
respective biopsies using the paired Student t-test (P < 0.05). 
HF-treated rats had 22.1% (2.9 ± 1.2) fewer regenerative 
nodules per microscopic field following treatment with HF 
than before the treatment with HF (biopsy; 3.8 ± 1.4). In 
contrast, in the PS group there was a 51.8% (5.5 ± 1.9) 
increase in the number of regenerative nodules after PS 
treatment compared with the biopsy material (3.6 ± 1.5). 
The total hepatic collagen in the HF group was reduced 
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by 29.6% (7.8 ± 1.9%) after treatment compared with the 
biopsy (11.1 ± 2.2%). The total collagen in the PS group 
increased by 8.7% (12.4 ± 3.5%) after the biopsy (11.4 ± 
2.4%). However, the difference was not statistically signifi-
cant. All the rats submitted to HF treatment (24 animals) 
showed reduction of total hepatic collagen. When the mean 
collagen contents of the unpaired HF group (6.6%) and of 
the PS group (14.3%) were compared, a 37.1% reduction 
was observed in the HF group.
Hepatic functions
The concentrations of blood serum marker proteins 
improved in the HF group, which showed a reduction 
in γ-glutamyl transferase (GGT; -43.1%, 2.9 ± 2.8 U/L), 
alanine aminotransferase (ALT; -17.6%, 51.5 ± 12.1 U/L), 
and aspartate aminotransferase (AST; -12.2%, 132 ± 36.7 
U/L) levels when compared with the PS group (GGT: 6.7 
± 5.7, ALT: 62.45 ± 15.6, AST: 142.5 ± 26.4 U/L; Figure 2). 
Mean ALT and AST levels of the HF group were statistically 
similar to control levels. 
Extracellular matrix modulation 
The relative expression of profibrotic mRNA (2D-DCT) 
was lower in the HF group compared with the PS group and 
similar to the control group, being statistically significant: 
collagen-α1 (-53%, 2.57 ± 1.86), TGF-β1 (-57.7%, 1.07 ± 
0.87), TIMP-1 (-31.7%, 1.81 ± 0.85), and MMP-2 (-41.6%, 
4.14 ± 1.87). Only mean MMP-2 was higher than the control 
group. The PS group values were significantly higher for 
the same genes: collagen-α1 (5.46 ± 2.67), TGF-β1 (2.53 
± 1.23), TIMP-1 (2.65 ± 1.32), and MMP-2 (7.09 ± 2.22). All 
values in this group were higher than control. The relative 
expression of the profibrinolytic Plau was similar in both 
treated groups, although higher than control (Figure 3). 
Progranulin and cell proliferation
Progranulin protein or mRNA positivity was absent 
from both cirrhotic and normal livers. However, weak 
mRNA positivity was found in duodenal intestinal crypts 
as expected from previous reports (11). PS and HF rats 
showed progranulin protein and mRNA positivity in pa-
Figure 1. Effect of hepatotrophic factors on thioacetamide-induced liver cirrhosis in rat. a, Liver section of a rat receiving 
physiologic saline. Extensive deposition of collagen is seen (arrows) among the regenerative nodules (star). b, Liver 
section of a rat from the group treated with hepatotrophic factors showing a reduction of inter- and intranodular collagen 
and thinning of fibrous septa (arrows) and regenerative nodules (star), and the reappearence of a centrolobular vein 
(arrowheads). c, Liver section of a control rat showing the normal parenchymal structure and a central vein (arrowhead). 
Picrosirius staining. Bar: 200 μm.
Figure 2. Serological markers of hepatic lesion γ-glutamyl transferase (GGT) (A), alanine aminotransferase (ALT) (B), and aspartate 
aminotransferase (AST) (C) for the control group and for the groups treated with hepatotrophic factors (HF) and receiving physiologic 
saline (PS, untreated). The means identified with different letters were significantly different (P < 0.05, Tukey test).
ECM modulation by hepatotrophic factors in  cirrhotic rats 1031
www.bjournal.com.br Braz J Med Biol Res 42(11) 2009
renchymal and non-parenchymal hepatic cells, mainly in 
proliferation zones of bile ducts and fibrous septa (Figure 
4b,c,e,f). These areas also had high proliferative activity 
(Figure 4a,d). Enterocytes of PS and HF animals were also 
positive to progranulin mRNA and protein in epithelial cells 
and, mainly in villi.
Figure 4. Photomicrographs of a cirrhotic liver from an untreated rat submitted to different techniques. a, High proliferation activity of bile 
duct epithelial cells is seen in the area of bile duct proliferation (arrows). b, Bile duct epithelial cells are strongly positive to progranulin 
(Pgrn) protein in a proliferation area (arrowhead). c, Progranulin in situ hybridization (ISH) in the area of bile duct proliferation. The bile 
duct epithelial cells are strongly positive. d, Non-parenchymal cells also show high proliferation activity in a fibrous septum area (arrows). 
e, Non-parenchymal cells show progranulin protein positivity (asterisk). f, Progranulin ISH in a fibrous septum area, showing high positiv-
ity of non-parenchymal cells (asterisk). Panels a and d are diaminobenzidine immunostaining and hematoxylin counterstaining. Panels b 
and e are diaminobenzidine immunostaining. BrdU = bromodeoxyuridine; IHC = immunohistochemistry. Bar: 100 μm. 
Figure 3. Relative expression 
activities of genes involved in 
extracellular matrix modula-
tion in the hepatotrophic factor 
group (HF, treated), physiolog-
ic saline group (PS, untreated), 
and control group. The means 
identified with different letters 
(a, b, c) were significantly differ-
ent (P < 0.05, Newman-Keuls 
test). Col-α1 = collagen-α1; 
TGF-β1 = transforming growth 
factor-β1; TIMP-1 = tissue in-
hibitor of metalloproteinase-1; 
MMP-2 = matrix metallopro-
teinase-2; Plau = plasminogen 
activator urokinase.
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Discussion
We studied the possible extracellular matrix modulation 
effects of HF composed by salts, vitamins, glucose, amino 
acids, and hormones on TAA-induced cirrhosis in rats. 
The slowly developing TAA cirrhosis model has proven 
to be morphologically well defined and uniform (16) and 
to resemble the major features of human cirrhosis, with 
less mortality than other models of chemical cirrhosis (17). 
Nevertheless, a problem in the TAA models (18-20) is that 
apparently the animals become adapted to the drug. After 
an initial weight loss during the first weeks of TAA admin-
istration, the rats began to regain weight. We solved this 
problem by increasing the TAA dose by 20% after the 7th 
week. The cirrhosis obtained was well-characterized, with 
abundant deposition of collagen in hepatic tissue. 
The increase of hepatic mass (11.8%) in animals treated 
with HF for 10 days was associated with the decrease of 
collagen volumetric proportion (37.1%). Therefore, the 
increase in mass is derived from functional tissue, such as 
hepatocytes and the circulatory system. The concomitant 
increase in the liver weight and LC index supports this theory. 
In normal rats it was shown that HF promoted a 45% increase 
in the hepatic mass (4). The values of liver mass, volume 
and LC index of the control group were lower than those 
of the PS group (cirrhotic not treated). Liver hypertrophy is 
normally expected in hepatic diseases, in this case it was 
probably due to the accumulation of extracellular matrix 
on the liver, cell proliferation in regenerative nodules and 
bile cell proliferation.
The serologic tests showed improvements of ALT, GGT, 
and AST levels after HF treatment. The 43% reduction of 
GGT, a sensitive indicator of biliary disease, compared to 
the PS group demonstrates that the HF solution stimulated 
liver recovery, with benefits to the biliary system. These 
results agree with the histopathologic findings, which re-
vealed decreased areas of bile duct proliferation after HF 
treatment. The reduction of ALT (-17.6%) and AST (-12.2%) 
also points to a reduced hepatocellular necrosis, decreasing 
the cycles of cell death and fibrotic regeneration that are 
characteristic of the cirrhotic process. Other treatments also 
improved hepatic conditions in fibrosis and cirrhosis models 
with down-regulation of enzymes of hepatic function, such 
as gliotoxin (21), hepatic growth factor (22), pirfenidone (23), 
vitamins C and E (24), urokinase plasminogen activator 
(25), and partial hepatectomy (26). 
The 37.1% reduction of parenchymal collagen when the 
groups were compared or the 29.6% reduction in biopsy-
paired comparisons after HF treatment of TAA cirrhosis is 
a promising finding. It is important to emphasize that the 
number of regenerative nodules in the cirrhotic liver of the 
untreated (PS) group increased by 51.9% after the TAA 
injections were stopped (as could be seen when biopsies 
were compared with material taken after 20 days), whereas 
in the HF groups there were 22.1% fewer nodules per 
microscopic field. Thus, the treatment of cirrhosis with HF 
was effective both in stopping the evolution of cirrhosis 
and mainly in reversing this condition. The reduction of 
deposition of collagen fibers in the hepatic parenchyma and 
the reduction in the number of regenerative nodules may 
contribute to the improvement of liver functions, since the 
hepatic blood system is favored by these events. Treatment 
with hepatocyte growth factor also reduced collagen content 
by 34% in a TAA model (27), in which, however, cirrhosis 
was induced only for 10 weeks. Virus therapy (adenovirus 
containing MMP-1) obtained a lower reduction of hepatic 
collagen (15 to 5%); however, the ALT level increased, 
indicating hepatocyte damage (19). Other substances 
have proven to be effective: vitamins C, E and C + E (24), 
losartan (28), gliotoxin (24), pirfenidone (29), relaxin (30), 
and Han-Dan-Gan-Lee (31) also reduced fibrosis in rat 
livers. Hepatic growth factor (22), halofuginone (32) and 
adenovirus with urokinase plasminogen activator (25) in-
duced collagen reduction in cirrhosis models. It should be 
pointed out that treatment with pirfenidone reduced 40% 
of the fibrosis induced by CCl4 (23).
Since we detected a significant reduction of collagen 
after just 10 days of treatment, it is very likely that a more 
prolonged treatment with HF could reduce collagen de-
position on the hepatic parenchyma even more, thereby 
contributing to a greater reversal of the cirrhosis condition, 
and could also be an important auxiliary treatment of fibro-
sis. In addition to the quantitative differences in collagen 
content between the treated and untreated groups, we also 
detected qualitative differences in liver structure after HF 
treatment. The HF-treated rats showed partial restoration 
of the hepatic parenchyma: the lobular architecture was 
closer to that found in healthy animals, with an easier 
identification of the portal vessels and centrolobular veins. 
Although the effect of some components of the HF solution 
has been previously studied (2-5), the amino acids and 
other nutritional components seem to act synergistically, 
providing the additional material and stimulus necessary 
to the rebuilding of the liver architecture disturbed by the 
cirrhotic process (6).
Although the antifibrotic effect of HF on cirrhotic livers 
was well characterized here, it is not possible to conclude 
that HF was actively profibrinolytic, because Plau, a gene 
which is directly and indirectly involved is fibrinolysis, was 
not affected by the treatments. The reduction of profibrotic 
gene expression by HF is consistent with previous reports 
on other substances that promoted collagen reduction in 
liver and that also reduced expression of profibrotic genes 
or increased profibrinolytic genes. Hepatocyte growth factor 
down-regulated the expression of collagen-α1 (46%) and 
TGF-β1 (57%) in liver cirrhosis, although the expression of 
TIMP-1 remained unchanged (26). In our experiment the 
expression of the profibrotic genes studied (collagen-α1, 
MMP-2, TGF-β1, and TIMP-1) was coherently down-reg-
ulated. Experiments with other substances have reported 
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variable results with respect to the expression of profibrotic 
genes, number of genes studied and model of fibrosis or 
cirrhosis. Sho-saiko-to (a Chinese herb) down-regulated 
the expression of TIMP-1 and up-regulated MMP-13, but it 
promoted up-regulation of the profibrotic gene MMP-2 (33). 
In fibrosis models, interleukin-10 down-regulated TIMP-1 
and MMP-2 (34); relaxin down-regulated collagen-α1 and 
TIMP-1 (30) and pirfenidone reduced TGF-β1, TIMP-1, 
and procollagen α1(I) production (29). In cirrhotic models, 
adenovirus with urokinase plasminogen activator, increased 
gene expression of collagenases (25), and halofuginone 
reduced gene expression of collagen-α1 (35). 
Progranulin protein and mRNA were found in hepatic 
and intestinal cells of cirrhotic rats. Although progranulin 
expression has been observed in LX-1 and LX-2 cell lines 
(activated HSC) in culture (10), and is elevated in models 
of liver steatohepatitis (9) and in hepatocellular carcinoma 
(36), the present study demonstrates for the first time that 
this new growth factor is up-regulated in cirrhotic livers in 
vivo. Both progranulin protein and mRNA positivity were 
strong in hepatic areas of bile duct proliferation and in fibrous 
septa. These areas coincide with high proliferative activity 
(demonstrated by BrdU nuclear incorporation), indicative of 
the involvement of this growth factor in bile duct epithelial 
cell and non-parenchymal cell proliferation, which contrib-
utes to the fibrotic process. As previously reported for other 
tissues, progranulin may be involved in the regulation of 
cell growth and in the inflammatory process that occurs in 
cirrhosis (37-40). Progranulin positivity (mRNA) in intestinal 
villus macrophages of cirrhotic rats also shows the influence 
of this protein on the inflammatory process. The expression 
of progranulin in TAA-treated rats, but not in healthy con-
trols, indicates that it could be a marker of hepatic lesions. 
However, more studies are needed to establish the role of 
progranulin in the cirrhotic process.
The present results show that HF treatment can down-
regulate the expression of profibrotic genes, collagen-α1, 
MMP-2, TIMP-1, and TGF-β1, with reduction of total hepatic 
collagen, partial restoration of the parenchymal structure and 
improvement of the blood levels of hepatic lesion markers 
(Table 1). These results may provide new insights for the 
nutritional treatment of cirrhosis.
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